The shares have sprung back to life thanks to China’s new stimulus programs—and Alibaba’s AI ventures. They stand to gain as much as 48%.

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Pursuant to Regulation 7(2)(b) of PIT Regulations 2015, Company has received "Form B" from Mr. Shreedhara Shetty, Non Executive and Non-Independent Director of the Company, in respect of sale of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

US President Donald Trump has again singled out Ireland's pharmaceutical industry as a target for tariffs. Trump was speaking as he announced 25% tariffs on cars and car parts imported into the US.

Trump has announced 25% tariffs on cars and car parts imported into the US US President Donald Trump has again singled out Ireland's pharmaceutical industry as a target for tariffs. Trump was ...

Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...

FRANKFURT, March 26 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe ...

Given the extent of India’s pharma exports to US, this has created a certain bit of uncertainty in the market. Trump said the US would impose tariffs on autos, pharmaceuticals and aluminum in ...

There remains much uncertainty about these measures, however. As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news.